Foundation Medicine Inc (FMI) SVP Sells $119,296.00 in Stock
Foundation Medicine Inc (NASDAQ:FMI) SVP Robert W. Hesslein sold 1,864 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $64.00, for a total value of $119,296.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Foundation Medicine Inc (FMI) opened at $65.70 on Friday. The company has a quick ratio of 2.03, a current ratio of 2.24 and a debt-to-equity ratio of 0.47. Foundation Medicine Inc has a one year low of $17.50 and a one year high of $70.75.
Foundation Medicine (NASDAQ:FMI) last posted its quarterly earnings results on Wednesday, November 1st. The company reported ($0.90) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.06) by $0.16. The firm had revenue of $42.66 million during the quarter, compared to the consensus estimate of $37.99 million. Foundation Medicine had a negative return on equity of 143.18% and a negative net margin of 119.69%. The business’s revenue was up 45.0% compared to the same quarter last year. During the same period last year, the company earned ($0.90) earnings per share. analysts anticipate that Foundation Medicine Inc will post -4.44 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Chevy Chase Trust Holdings Inc. boosted its stake in shares of Foundation Medicine by 1.1% during the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 1,059,141 shares of the company’s stock worth $42,572,000 after acquiring an additional 11,934 shares during the period. Discovery Group I LLC boosted its stake in shares of Foundation Medicine by 0.9% during the 3rd quarter. Discovery Group I LLC now owns 836,986 shares of the company’s stock worth $33,647,000 after acquiring an additional 7,181 shares during the period. Oppenheimer & Co. Inc. boosted its stake in shares of Foundation Medicine by 5.8% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 723,480 shares of the company’s stock worth $29,084,000 after acquiring an additional 39,390 shares during the period. Vanguard Group Inc. boosted its stake in shares of Foundation Medicine by 8.2% during the 2nd quarter. Vanguard Group Inc. now owns 631,339 shares of the company’s stock worth $25,096,000 after acquiring an additional 47,843 shares during the period. Finally, Lord Abbett & CO. LLC boosted its stake in shares of Foundation Medicine by 146.0% during the 2nd quarter. Lord Abbett & CO. LLC now owns 579,225 shares of the company’s stock worth $23,024,000 after acquiring an additional 343,770 shares during the period. Institutional investors own 32.68% of the company’s stock.
A number of research analysts have weighed in on FMI shares. BidaskClub upgraded Foundation Medicine from a “hold” rating to a “buy” rating in a research note on Saturday, September 9th. Zacks Investment Research downgraded Foundation Medicine from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $45.33.
WARNING: “Foundation Medicine Inc (FMI) SVP Sells $119,296.00 in Stock” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.watchlistnews.com/foundation-medicine-inc-fmi-svp-sells-119296-00-in-stock/1797174.html.
Foundation Medicine Company Profile
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with Analyst Ratings Network's FREE daily email newsletter.